2022 Galenica Group sales

The Galenica Group can once again look back on an exceptionally successful 2022 financial year: consolidated net sales increased by 4.7% to CHF 4,014.3 million. As a result, Galenica slightly exceeded its sales forecast and passed the CHF 4 billion mark for the first time.

Adjusted for additional sales in connection with COVID-19, which were exceptionally high in the prior-year, sales growth was even high at 7.1%. After a normal seasonal flu epidemic and numerous illnesses caused by the coronavirus Omicron variant led to strong growth in the first half of the year 2022, sales for the entire Group were also influenced in the second half of the year by a strong, early-onset flu epidemic. This had a particular impact on the Products & Brands sector, which grew at an above-average rate of 19.8%. In addition, the extremely positive growth momentum of the previous year was continued in the 2022 financial year by the specialty pharmacy Mediservice (+12.9%).

Based on adjusted¹ EBIT 2021 – excluding the extraordinary results from the COVID-19 initiatives (estimated at CHF 25 million) and the property sale at its headquarters in Bern (CHF 9.4 million) – an expected EBIT increase of 8% to 12% was communicated with the 2022 half-year results. Thanks to the strong sales growth in the second half of 2022, Galenica expects an EBIT increase at the upper end of this range.

^{1 Excluding the effects of IFRS 16 and IAS 19}

Additional information on sales figures and further information can be found in our investor presentation.